在阿尔茨海默氏病中,FTIR光谱和血液衍生的细胞外囊泡双重作用

相关实验视频

Updated: May 13, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Tânia Soares Martins¹, Maria Ferreira¹, Sandra Magalhães^2,3,4

¹Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.

Journal of Alzheimer's disease : JAD

|March 15, 2024

概括

用福里埃变换红外光谱 (FTIR) 分析的血液细胞外囊 (EV) 显示了阿尔茨海默病 (AD) 诊断的独特光谱特征. 这种方法提供了一个有前途的新工具,用于使用血液样本早期检测AD.

科学领域:

生物化学生物化学
频谱学是一种光谱学.
神经科学是一个神经科学.

背景情况:

阿尔茨海默病 (AD) 诊断仍然具有挑战性,需要使用外围生物流体的新工具.
血液中的细胞外囊泡 (EVs) 是有前途的生物标志物,因为它们的疾病特异性载荷.
福利埃变换红外光谱 (FTIR) 提供了一种分析EV组成的方法,包括脂质,蛋白质,碳水化合物和核酸.

研究的目的:

为了确定血源EV (bdEV) 中的光谱特征,可以区分阿尔茨海默病 (AD) 病例和对照病例.
评估bdEVs的FTIR光谱作为AD的诊断工具的潜力.

主要方法:

从AD患者和对照个体的血清和血中分离的bdEV获得FTIR光谱.
分析频谱数据,重点关注不同频谱区域的峰值区域.
与碳水化合物,核酸,胺和脂质等分子成分相关的光谱差异的表征.

主要成果:

在AD病例和对照群之间观察到bdEVs的第二衍生峰值区域的显著差异.
这些光谱差异局限于与碳水化合物,核酸,胺和脂质相关的区域.
bdEVs的FTIR光谱图表显示了对AD进行歧视的潜力.

结论:

使用FTIR对bdEV的光谱分析显示了AD诊断的前景.
与FTIR光谱学相结合的bdEV可以作为AD检测的查或补充工具.
这种方法突显了外围生物流体衍生的电子电路在开发可访问的神经退行性疾病的诊断方法中的实用性.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.生物标志物生物标志物诊断诊断诊断诊断诊断诊断细胞外囊泡中的细胞外囊泡.脂质脂质脂质是一种核酸是核酸中的一种.蛋白质是一种蛋白质.

更多相关视频

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma

Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma

Published on: August 3, 2022

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...